Leerink Swann assumed coverage on shares of Abeona Therapeutics (NASDAQ:ABEO) in a report issued on Monday morning, TipRanks reports. The brokerage issued a buy rating and a $6.00 target price on the biopharmaceutical company’s stock.

Several other brokerages have also weighed in on ABEO. HC Wainwright began coverage on Abeona Therapeutics in a research report on Tuesday, January 21st. They issued a buy rating and a $11.00 price objective for the company. Zacks Investment Research lowered Abeona Therapeutics from a buy rating to a hold rating in a research report on Tuesday, October 15th. ValuEngine upgraded Abeona Therapeutics from a hold rating to a buy rating in a research report on Tuesday, December 3rd. Cantor Fitzgerald began coverage on Abeona Therapeutics in a research report on Tuesday, December 10th. They issued a hold rating and a $4.00 price objective for the company. Finally, Svb Leerink began coverage on Abeona Therapeutics in a research report on Monday. They issued an outperform rating and a $6.00 price objective for the company. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $7.18.

NASDAQ:ABEO opened at $3.09 on Monday. The stock has a market cap of $161.63 million, a PE ratio of -1.94 and a beta of 2.16. Abeona Therapeutics has a one year low of $1.46 and a one year high of $8.41. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.45 and a current ratio of 2.45. The stock has a 50 day moving average price of $2.72 and a 200 day moving average price of $2.68.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.09. As a group, analysts predict that Abeona Therapeutics will post -1.52 earnings per share for the current fiscal year.

In other news, Director Stefano Buono purchased 200,000 shares of the stock in a transaction dated Tuesday, December 24th. The stock was acquired at an average cost of $2.50 per share, for a total transaction of $500,000.00. Following the completion of the transaction, the director now directly owns 270,000 shares in the company, valued at approximately $675,000. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 33.60% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Northern Trust Corp boosted its holdings in Abeona Therapeutics by 2.0% during the 2nd quarter. Northern Trust Corp now owns 408,134 shares of the biopharmaceutical company’s stock valued at $1,951,000 after acquiring an additional 7,824 shares during the period. Parametric Portfolio Associates LLC purchased a new position in Abeona Therapeutics during the 2nd quarter valued at $74,000. BlackRock Inc. raised its position in Abeona Therapeutics by 5.9% during the 2nd quarter. BlackRock Inc. now owns 2,459,931 shares of the biopharmaceutical company’s stock valued at $11,759,000 after purchasing an additional 137,558 shares in the last quarter. Vanguard Group Inc. raised its position in Abeona Therapeutics by 11.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,828,699 shares of the biopharmaceutical company’s stock valued at $8,742,000 after purchasing an additional 193,618 shares in the last quarter. Finally, Cubist Systematic Strategies LLC bought a new stake in Abeona Therapeutics during the 2nd quarter valued at $196,000. Institutional investors and hedge funds own 56.80% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Recommended Story: Beige Book

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.